11.11.19|Uri Tal-TeneWith one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
08.01.19|Lilach Baumer and Hezi SternlichtSpeaking at J.P. Morgan’s Healthcare Conference on Monday, CEO Kåre Schultz said he expects the U.S. generic market to stabilize in 2019